euro adhoc: Marseille-Kliniken AG
Financial Figures/Balance Sheet
- Increase
in turnover in the financial year 2007/2008 to EUR 228.1 m
- Consolidated net income reaches EUR 1.14 per share
- Surge in profits in the Rehabilitation segment
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
annual report
31.10.2008
Berlin, 31 October 2008. Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) was able to accelerate its growth in the financial year and considerably increase its results against the previous period. Consolidated turnover in the financial year 2007/2008 increased to EUR 228.1 m (previous year: EUR 214.8 m). The annual surplus after minority interest improved from EUR 9.1 m to EUR 13.8 m. This considerable increase in the unadjusted result can be mainly attributed to extraordinary gains from another sale-and-lease-back transaction as well as income from the adjustment of deferred taxes in the run-up to the German corporation tax reform 2008. This amounts to earnings per share of EUR 1.14 compared to EUR 0.75 in the previous year.
EBIT include other taxes reached EUR 22,1 m against EUR 23.3 m in the previous year. EBITDAR reached EUR 73.8 m and was above previous year levels (EUR 69.6 m). Equity amounted to EUR 84.0 m compared to EUR 71.2 m in the previous year, corresponding to an equity ratio of 35.1% (previous year: 23.0%).
Earnings according to DVFA/SG (IFRS) reached EUR 11.2 m in the financial year compared to EUR 10.5 m in the previous year. This amounts to EUR 0.93 per share (previous year: EUR 0.86). EBITDAR increased slightly against the previous year from EUR 61.8 m to EUR 62.6 m. EBIT fell to EUR 17.5 m (previous year: EUR 20.2 m).
At the end of the financial year the Care segment reached a capacity of 7,616 beds (previous year: 7,287 beds) in 56 institutions. In the period under review turnover increased from EUR 166.5 m to EUR 176.4 m. Earnings according to DVFA fell from EUR 12.7 m in the previous year to EUR 7.2 m Soft results in Care segment can be mainly attributed to a significant increase in energy costs due to adverse weather conditions as well as the development of food prices. In addition to that, the company made a one-off pre-payment of EUR 1.5 m for the comprehensive implementation of an eLearning platform for groupwide quality management for 2800 employees. Occupancy levels in Care were continually increased against the market trend and reached an average value of 93.3% compared to 92.8% in the previous year. At group level occupancy was also increased and reached 92.4% at a capacity of 8,899 beds compared to 89.7% in the previous year.
The Rehabilitation segment was again able to increase its positive contribution to turnover and profits at group level, despite further reducing bed capacity. Bed capacity dropped from 1,478 in the previous year to its current total of 1,283 beds in nine institutions. Occupancy was again considerably optimized and increased from 75.9% in the previous year to 90.4% in the full year. Turnover in Rehabilitation improved from EUR 48.3 m in the previous year to EUR 51.7 m in the period under review. The result according to DVFA/SG (IFRS) reached EUR 4.0 m marking a significant leap into profitability (previous year: EUR -2.2 m).
In the current financial year capacities are being expanded further. The company already opened a new facility in Meerbusch back in July. More Care facilities are planned for Oberhausen and Waldkirch. The company is confident that the 2-Star concept has significant growth potential and it is therefore being applied consistently. Market analysis for suitable locations and facilities for the concept has been completed. The company is expecting to be implementing 3,000 residential units in the next three years, which would then increase total capacity to 12,000 beds.
For the current and the following financial year the company is expecting growth of at least 6.5% annually. Turnover and earnings are going to be positively impacted by the continual increase in occupancy, especially in the facilities involved in the expansion plans. The company is expecting an EBIT return of at least 7% in the financial year 2008/2009.
The annual report for the business year 2007/2008 will be published today at the company´s homepage www.marseille-kliniken.com. The results for the first quarter of the current business year 2008/2009 will be announced on 10. November.
End of ad hoc release
end of announcement euro adhoc
Further inquiry note:
Marseille-Kliniken AG
Axel Hölzer
CEO
Alte Jakobstraße 79/80
10709 Berlin
Germany
Tel.: +49 30 / 246 32-400
Fax: +49 30 / 246 32-401
www.marseille-kliniken.com
Hillermann Consulting
Christian Hillermann
Investor Relations Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Germany
Tel.: +49 40 / 320 279 10
Fax: +49 40 / 320 279 114
www.hillermann-consulting.de
Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hamburg / regulated dealing